This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mental Health Care In California Prisons Still In Crisis

SAN FRANCISCO, March 18, 2013 /PRNewswire/ -- Lawyers representing prisoners with serious mental illness in California state prisons filed their opposition to the State of California's motion to terminate Coleman v. Brown – the long-running lawsuit that led to a U.S. Supreme Court decision in 2011 that California must reduce prison overcrowding to address constitutional violations and inhumane treatment of the mentally ill in California's prisons. The motion will be argued in federal court in Sacramento on March 27.

The 99-page brief, which is supported by hundreds of pages of expert testimony from some of the nation's leading experts in prison reform and mental health care, provides overwhelming evidence that the State has failed to follow court orders and the recommendations of its own staff and experts to address horrific conditions and violent, inhumane treatment of the mentally ill in state prisons – contributing to a suicide rate among prisoners that is far above the national average.

"The State, with Governor Brown cynically leading the charge, would like you to believe that the prison mental health care crisis has disappeared simply because they say it is so," said Michael Bien of Rosen Bien Galvan & Grunfeld, lead attorney for the Coleman class. "Realignment and a reduction in the prison population provided an opportunity for the state to solve the mental health crisis – instead the administration has gone on a PR and litigation offensive, rather than taking simple, affordable steps to change a dangerously flawed system."

Bien continued, "The State maximized budget savings through massive layoffs of clinical staff, and cancellations and delays of building and upgrade projects, forcing overworked clinicians to work double-duty to take care of seriously ill patients in the same dangerous and inappropriate offices and treatment spaces that the Supreme Court found to be unconstitutional less than two years ago."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%
YHOO $26.76 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs